EDITORIAL



Sicong Zhang, Xianming Liu, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianhuo Wang, Huilai Zhang

Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China

Treatment strategies for early-stage HL

Т	_a_af	HL a
a		.a
	a_HL), _a ,a a,	faT -
	faa fHLaa	a- <u>a</u> a_a

2.

Treatment options for advanced HL

PD1 antibody

Progress in developing novel therapies for HL in 2023

Study population

| <u>+</u>

S, a _ a, _ ff a a a, (17-ICML), H a _ a $.^{3}$ a - - f. SWOG S1826 _ , a _ a _ a _ . a BV-AVD, a' (N)-AVD PFS a a <u>f</u>, a a a a-, a, a <u>a</u> HL. T a <u>a</u>-____a_f a____a_a HL. H, , _a , _ f , - _ , a _, a , a , , a (OS) f_{-1} a f_{-1} , a, ff f a a AVD (, . . , , a aala ; APVD) a HL. T 2- a PFS a OS, 97% a 100%, , a fa a' af a ff a ¹⁴. A _____a, ___a__a___-PD1 a__1 a<u>-</u> - 1 - 1 ___a a ff ___ HL. а F a_aa_HLa__,a ff______ f___a_____ a______ **_**__a a_, . T C ' O G (COG) a a <u>a</u> a fa a' a_ a_ _ _ a_30 a. a____. H₁, , - *f*₁ - *a*, , a ___ a__ - a_ a , f - - , a_, а _ _f a__ a fa, , a 🔔 , _a_f_aaa__.Tf, f_ a a a 1 <u>,</u> f a <u>,</u> a , a a <u>,</u> _ fa_aa ۶ -____a, *ff*___.T ____ a___ "a," ____a 2(). ____,-/, , , a a a a (COPDAC-28) -

a, 7P, a, a a a' af, a a, ff, a, a, f()17_(a) 2.9()10.1()TJ0.162 T, 0-1.474 TD(a)17(. a)-2()3(.)

_ A__2 (P) 1 COPDAC-28-(a35((1.5(1(_ a7P)Ta)-21(4_1 ()T0f)) IT] 0.155 T3) - 117 (a 3 h T) -)-36 4) 9(2) 36 J) - 3(a(3(

, 6 a a - 3 0 (.1) 3 () T J .9. a 5 () 3 2 7 P _ a a V 1 1 (

(95% CI 84-98), a a BV a a ff a a R/R HL⁷. T a R/R HL 1 _____PD-1 _____,4 a II___a a a, £ C a. A. a f 260 a _aa.Na -ff_fa_a,a, fa a a fa a , a , a 3- a PFS a______a PFS, a____a 50%⁸. T______f, a____a a a a a a _a__a afa___a_a af PD-1 a a a.

Taf HL, af f, a _, a a _, (CAYA) , 1 90%. H, , , , , fa, a , , a , a, 10% fa_a, a.U_a -H'al, HL, a, l, a a, a, *ff*, a a ff. a . FR/RHL CAYA, C Ma, 744 , a , a, a -__a_f, -a a____, a' BV, f, BV a I ... , a BV a CMR a f 59% a , a f a_{-} , a_{-} , $BV \pm BV$, a_{-} , a_{-} ______ a CMR a_____ f 94%. A CMR a______ CAYA a ____ R/R HL af f_{--} -a a , - , a f a, a , a $\frac{9}{--}$.

Bispecific antibody

CAR-T therapy

 $af_{-vs.-}$ a^{-15} . T a f $af_{-vs.-}$ a, a_{--} 17-ICML, a_{--} , a f a_{--} a R/R HL. E -Ba - f T (EBVST), f a_{--} fa CAR f_{--} a_{--} a_{---} a_{---} a_{--} a_{--}

Treatment options for older patients

I $a_{1} > 60 a f a$, a_{2} , a_{3} _ a a _ a a _ a a _ a fa a' _ fa_ . C _ , _ a a -_ f a a a , a f_____a'____a_____. _ a_ _ f a, HL, ABVD, a, a , a a'.A__a £72% £ a__a , a , a 32% a 3 a, , , , , a, . ____a_____-a a a . A a a _ a_ ffaa_-_ a__ N-AVD a' a a f a f a f a HL^{13} . T f , a a a a la, al <u>a</u> f a <u>a</u> a, a HL.

Conclusions

T a a fHL, $a_{a}a_{f}$ a_{-} a a l a a a fa_{-} , , f a a a a_{-} a a_{-} a_{-} f a a a_{-} a_{-} a_{-} f a a_{-} a_{-} a_{-} a_{-} f a a_{-} a_{-} a_{-} a_{-} f a BV a_{-} -PD1 a_{-} f a BV a_{-} -PD1 a_{-} f a a_{-} a_{-} a_{-} a_{-} a_{-} a